Home › Calculator › TAK Dividend Calculator 2026
TAK DRIP Calculator & Dividend Yield 2026
3.10% YieldHealthcareTakeda Pharmaceutical Company Limited · NYSE
Price: $20.24 · Annual div: $0.6269/share · Frequency: semi-annual · Payout ratio: 1% · Ex-div: 2026-09-29
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When TAK pays your bills
Year your monthly dividend income covers each expense (based on current settings)
TAK Dividend History — Last 36 Payments
| Ex-Dividend Date | Payment Date | Amount / Share | TTM Yield | Stock Price |
|---|---|---|---|---|
| 2026-09-29Latest | — | $0.3970 | 5.64% | $18.23 |
| 2026-03-31 | 2026-07-06 | $0.3083 | 3.42% | $18.44 |
| 2025-09-30 | 2025-12-11 | $0.3221 | 3.95% | $15.16 |
| 2025-03-31 | 2025-07-07 | $0.2760 | 4.06% | $14.84 |
| 2024-09-30 | 2024-12-12 | $0.3261 | 4.14% | $14.92 |
| 2024-03-27 | 2024-07-08 | $0.2922 | 6.33% | $14.56 |
| 2023-09-28 | 2023-12-11 | $0.3191 | 6.23% | $15.39 |
| 2023-03-30 | 2023-07-10 | $0.3100 | 4.19% | $15.28 |
| 2022-09-29 | 2022-12-12 | $0.3296 | 4.80% | $13.74 |
| 2022-03-30 | 2022-07-11 | $0.3301 | 4.83% | $15.06 |
| 2021-09-29 | 2021-12-13 | $0.3969 | 4.75% | $16.91 |
| 2021-03-30 | 2021-07-12 | $0.4066 | 4.93% | $16.98 |
| 2020-09-29 | 2020-12-11 | $0.4305 | — | — |
| 2020-03-30 | 2020-07-06 | $0.4190 | — | — |
| 2019-09-27 | 2019-12-12 | $0.4111 | — | — |
| 2019-03-27 | 2019-06-28 | $0.3552 | — | — |
| 2018-09-26 | 2018-12-13 | $0.3955 | — | — |
| 2018-03-27 | 2018-07-09 | $0.4064 | — | — |
| 2017-09-27 | 2017-12-11 | $0.3995 | — | — |
| 2017-03-29 | 2017-07-10 | $0.3989 | — | — |
| 2016-09-29 | 2016-12-12 | $0.3924 | — | — |
| 2016-03-30 | 2016-07-11 | $0.4370 | — | — |
| 2015-09-29 | 2015-12-11 | $0.3653 | — | — |
| 2015-03-30 | 2015-07-09 | $0.3653 | — | — |
| 2014-09-28 | 2014-12-11 | $0.3783 | — | — |
| 2014-03-27 | 2014-07-10 | $0.4437 | — | — |
| 2013-09-26 | 2013-12-12 | $0.4370 | — | — |
| 2013-03-27 | 2013-07-08 | $0.4571 | — | — |
| 2012-09-26 | 2012-12-13 | $0.5460 | — | — |
| 2012-03-28 | 2012-07-09 | $0.5638 | — | — |
| 2011-09-28 | 2011-12-12 | $0.5786 | — | — |
| 2011-03-29 | 2011-07-07 | $0.5558 | — | — |
| 2010-09-28 | 2010-12-13 | $0.5332 | — | — |
| 2009-09-25 | 2009-12-15 | $0.5178 | — | — |
| 2009-03-26 | 2009-07-14 | $0.4818 | — | — |
| 2008-09-25 | 2008-12-16 | $0.4681 | — | — |
About Takeda Pharmaceutical Company Limited (TAK) — Dividend Analysis 2026
Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig. To further its innovative endeavors, Takeda engages in a wide array of strategic partnerships. These include out-licensing arrangements, notably with Neurocrine Biosciences, Inc.; numerous collaboration and in-licensing agreements with institutions like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., Ovid Therapeutics Inc., and Evox Therapeutics Ltd.; and a licensing deal with ProThera Biologics Inc. The company also fosters research collaborations and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio. Furthermore, it maintains strategic alliances with Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc., Carmine Therapeutics, KSQ Therapeutics, and Anima Biotech. Founded in 1781, Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan.
Similar dividend stocks to TAK
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full TAK DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open TAK position with:
🌍 TAK Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold TAK.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 3.10% | 0.30% | $310 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 2.63% | -0.17% | $264 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 2.48% | -0.32% | $248 / yr |
| 🇬🇧 UK ISA | 0% | 3.10% | 0.30% | $310 / yr |
| 🇬🇧 UK Taxable | 8.75% | 2.83% | 0.03% | $283 / yr |
| 🇨🇦 TFSA | 0% | 3.10% | 0.30% | $310 / yr |
| 🇨🇦 CA Taxable | 25% | 2.33% | -0.47% | $233 / yr |
| 🇦🇺 Super (pension) | 15% | 2.63% | -0.17% | $264 / yr |
| 🇦🇺 AU Taxable | 30% | 2.17% | -0.63% | $217 / yr |
| 🇩🇪 DE Taxable | 26.375% | 2.28% | -0.52% | $228 / yr |
| 🇫🇷 FR Taxable | 30% | 2.17% | -0.63% | $217 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 TAK Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $0.63/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 TAK Dividend Payment Schedule
TAK pays quarterly — 4 times per year. Ex-div: 2026-09-29.
📊 TAK vs Healthcare Benchmarks
How TAK compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for TAK sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ TAK Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Sale | 2026-09-14 | 34,535 | $18.54 | $640.3K | ||
| Sale | 2026-09-02 | 116,191 | $18.49 | $2.15M | ||
| Sale | 2026-08-19 | 19,651 | $18.49 | $363.3K | ||
| Sale | 2026-08-18 | 12,980 | $18.11 | $235.1K | ||
| Sale | 2026-08-10 | 14,006 | $17.10 | $239.5K | ||
| Sale | 2026-08-10 | 7,277 | $17.10 | $124.4K | ||
| Sale | 2026-08-10 | 16,901 | $17.10 | $289.0K | ||
| Sale | 2026-08-10 | 47,586 | $17.10 | $813.7K | ||
| Sale | 2026-08-10 | 165,393 | $17.10 | $2.83M | ||
| Sale | 2026-08-10 | 22,957 | $17.10 | $392.6K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Peer Group
Similar companies in the same sectorCompare TAK with peers: TAK vs A · TAK vs ALC · TAK vs BDX
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where TAK earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the TAK dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Takeda Pharmaceutical Company Limited (TAK) is currently trading at $20.24, trading near its 52-week high. The current dividend yield is 3.10% based on an annual payout of $0.6269 per share.
TAK (Takeda Pharmaceutical Company Limited) — 3.10% Dividend Yield Analysis
Takeda Pharmaceutical Company Limited (TAK) is a healthcare stock currently trading at $20.24 with a dividend yield of 3.10%. It pays an annual dividend of $0.6269 per share. The payout ratio of 1% suggests the dividend is well-covered by earnings. Over the past 5 years, TAK has grown its dividend at a compound annual rate of 1.8%.
- Dividend payments are not guaranteed and can be reduced or suspended at any time.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest TAK News
LiveHow investors use the TAK dividend calculator
Illustrative examples of common use cases, written by the DividendFlow team — not customer reviews.